About Contact Us Careers

Candidiasis Drugs Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 3650
Published Date: Aug 26, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Candidiasis Drugs Landscape

Biogen, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Pfizer Inc.
Glenmark Pharmaceuticals
Merck KGaA
Novartis AG
Sanofi-aventis Groupe
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH
Daiichi Sankyo Company, Limited
Siemens Healthcare GmbH

Browse Key Market Insights with Data Illustration:

Candidiasis Drugs Market Size & Share, Forecast Report 2036

In the News

June, 2021: Novartis AG announced its collaboration with Hewlett Packard Enterprise to expand its distribution globally.
August, 2017: Sanofi-aventis and Bristol-Myers Squibb Company announced FDA approval for the antiplatelet agent PLAVIX.

Author Credits: Radhika Pawar

Report ID: 3650
Published Date: Aug 26, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of candidiasis drugs is estimated at USD 862.43 million.

Candidiasis Drugs Market size was over USD 822.3 million in 2023 and is anticipated to reach USD 1.77 billion by 2036, witnessing around 6.1% CAGR during the forecast period i.e., between 2024-2036. The increasing cases of candidiasis will boost the market growth.

Asia Pacific industry is predicted to account for largest revenue share by 2036, driven by climatic conditions that promote yeast infection.

The major players in the market are Pfizer Inc., Glenmark Pharmaceuticals, Merck KGaA, Novartis AG, Sanofi-aventis Groupe, Teva Pharmaceutical Industries Ltd., and others.

Inquiry Before Buying Request Free Sample